Quick Comparison

NMN (Nicotinamide Mononucleotide)Vitamin D3
Half-Life2-3 minutes in blood (rapidly converted to NAD+). NAD+ half-life: 1-2 hours in tissue15-25 days
Typical DosageStandard: 250-1000 mg daily. Sublingual may improve bioavailability by bypassing first-pass metabolism. Take in the morning — NAD+ follows circadian rhythm and morning supplementation aligns with natural peaks. Effects build over weeks.Standard: 2000-5000 IU daily. Optimal blood level: 40-60 ng/mL (100-150 nmol/L). Most adults need 4000-5000 IU to reach optimal levels. Take with fat for absorption. Get blood levels tested before supplementing — both deficiency and excess are harmful.
AdministrationOral (capsules, powder, sublingual). Sublingual may improve bioavailability. Store in cool, dry place.Oral (softgels, drops, tablets). D3 (cholecalciferol) preferred over D2 (ergocalciferol). Take with a fat-containing meal.
Research Papers10 papers10 papers
Categories

Mechanism of Action

NMN (Nicotinamide Mononucleotide)

NMN is transported into cells via the Slc12a8 transporter (highly expressed in the small intestine and brain) and converted to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNAT1 in the nucleus, NMNAT2 in axons/Golgi, NMNAT3 in mitochondria). Elevated NAD+ activates the sirtuin family of NAD+-dependent protein deacetylases: SIRT1 deacetylates PGC-1alpha to promote mitochondrial biogenesis, SIRT3 activates superoxide dismutase 2 (SOD2) and isocitrate dehydrogenase 2 (IDH2) for mitochondrial antioxidant defense, and SIRT6 promotes base excision repair of oxidative DNA damage. NAD+ is also consumed by poly(ADP-ribose) polymerases (PARP1/2) during DNA repair — age-related NAD+ depletion impairs PARP function, allowing DNA damage accumulation. In neurons, NAD+ is required for glycolysis (GAPDH cofactor), the TCA cycle, and Complex I of the electron transport chain, directly fueling the enormous ATP demands of synaptic transmission. NAD+ decline with aging (approximately 50% reduction between ages 40-60) reduces all of these processes simultaneously, creating a cascade of mitochondrial dysfunction, impaired DNA repair, and neuroinflammation that NMN supplementation aims to reverse.

Vitamin D3

Vitamin D (1,25-dihydroxyvitamin D3) crosses the blood-brain barrier and binds to vitamin D receptors (VDR), a nuclear receptor expressed on neurons, astrocytes, microglia, and oligodendrocytes. VDR heterodimerizes with RXR and binds vitamin D response elements (VDREs) to regulate transcription. It upregulates neurotrophic factors: GDNF (glial cell line-derived), NGF, NT-3 via CREB and other transcription factors. Vitamin D promotes serotonin synthesis by upregulating tryptophan hydroxylase 2 (TPH2) and dopamine synthesis via tyrosine hydroxylase. It reduces neuroinflammation by suppressing microglial IL-1beta, TNF-alpha, and iNOS, and supports calcium homeostasis via regulation of L-type voltage-gated calcium channels and calbindin-D28k. Vitamin D regulates over 200 genes including those for neuroprotection, synaptic plasticity, and myelination.

Risks & Safety

NMN (Nicotinamide Mononucleotide)

Common

Mild flushing, nausea, headache initially.

Serious

Long-term human safety data still limited (first human trials completed 2020-2023). Theoretical concern about promoting cancer growth in existing tumors (NAD+ fuels fast-growing cells).

Rare

Insomnia if taken late.

Vitamin D3

Common

Generally very safe at standard doses.

Serious

Toxicity at very high doses (>10,000 IU daily for months) — causes hypercalcemia (nausea, kidney stones, cardiac arrhythmia).

Rare

Headache, metallic taste, nausea.

Full Profiles